2165699-77-2 Usage
Description
(2S,3R)-1-(tert-butoxycarbonyl)-3-methoxypyrrolidine-2-carboxylic acid is a pyrrolidine-2-carboxylic acid derivative featuring a tert-butoxycarbonyl (Boc) protecting group and a methoxy group. Its stereochemistry of 2S and 3R denotes the specific orientation of substituents on the pyrrolidine ring, making it a versatile building block in organic synthesis, particularly for pharmaceutical applications.
Uses
Used in Pharmaceutical Industry:
(2S,3R)-1-(tert-butoxycarbonyl)-3-methoxypyrrolidine-2-carboxylic acid serves as a key building block for the synthesis of complex molecules, playing a crucial role in the development of new drug candidates. Its presence aids in the creation of molecules with potential therapeutic applications, contributing to advancements in medicinal chemistry.
Used in Organic Synthesis:
In the realm of organic chemistry, (2S,3R)-1-(tert-butoxycarbonyl)-3-methoxypyrrolidine-2-carboxylic acid is utilized for its selective reactivity due to the Boc protecting group. This feature allows chemists to perform specific reactions and manipulations, facilitating the synthesis of intricate organic compounds with desired properties and functions.
Check Digit Verification of cas no
The CAS Registry Mumber 2165699-77-2 includes 10 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 7 digits, 2,1,6,5,6,9 and 9 respectively; the second part has 2 digits, 7 and 7 respectively.
Calculate Digit Verification of CAS Registry Number 2165699-77:
(9*2)+(8*1)+(7*6)+(6*5)+(5*6)+(4*9)+(3*9)+(2*7)+(1*7)=212
212 % 10 = 2
So 2165699-77-2 is a valid CAS Registry Number.
2165699-77-2Relevant articles and documents
TRICYCLIC PI3K INHIBITOR COMPOUNDS AND METHODS OF USE
-
, (2018/03/25)
Described herein are tricyclic compounds with phosphoinositide-3 kinase (PI3K) modulation activity or function having the Formula I structure: or stereoisomers, tautomers, or pharmaceutically acceptable salts thereof, and with the substituents and structural features described herein. Also described are pharmaceutical compositions and medicaments that include the Formula I compounds, as well as methods of using such PI3K modulators, alone and in combination with other therapeutic agents, for treating diseases or conditions that are mediated or dependent upon PI3K dysregulation.
